Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy
Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy
Monoclonal antibodies (mAbs) have inaugurated the concepts of tumor-targeted therapy and personalized medicine. A new family of mAbs is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune-targeted therapies have recently demonstrated long-term tumor responses in adults with refractory/relapsing metastatic solid tumors. Pediatric cancers are different from their adult counterparts in terms of histological features and immune infiltrates. However, the same immune checkpoint targets can be expressed within the microenvironment of pediatric tumors. The benefits of immune checkpoint blockade in pediatric cancers are currently under evaluation in early phase clinical trials.
1317-1325
Marabelle, Aurelien
ad2b5945-3ba6-4993-b547-bd9a8cbfe863
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
August 2015
Marabelle, Aurelien
ad2b5945-3ba6-4993-b547-bd9a8cbfe863
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Marabelle, Aurelien and Gray, Juliet
(2015)
Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
Pediatric Blood and Cancer, 62 (8), .
(doi:10.1002/pbc.25508).
(PMID:25808079)
Abstract
Monoclonal antibodies (mAbs) have inaugurated the concepts of tumor-targeted therapy and personalized medicine. A new family of mAbs is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune-targeted therapies have recently demonstrated long-term tumor responses in adults with refractory/relapsing metastatic solid tumors. Pediatric cancers are different from their adult counterparts in terms of histological features and immune infiltrates. However, the same immune checkpoint targets can be expressed within the microenvironment of pediatric tumors. The benefits of immune checkpoint blockade in pediatric cancers are currently under evaluation in early phase clinical trials.
This record has no associated files available for download.
More information
Accepted/In Press date: 3 February 2015
e-pub ahead of print date: 21 March 2015
Published date: August 2015
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 396808
URI: http://eprints.soton.ac.uk/id/eprint/396808
ISSN: 1545-5009
PURE UUID: 0edd5697-e3df-4562-a9db-d7bbe816b83a
Catalogue record
Date deposited: 14 Jun 2016 13:02
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
Aurelien Marabelle
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
